Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: An economic evaluation alongside a 6-month randomized controlled trial

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Luciano, Juan V ^a,b,c   D'Amico, Francesco ^d   Cerdà Lafont, Marta ^a   Peñarrubia María, María T ^b,e   Knapp, Martin ^b,d   Cuesta Vargas, Antonio I ^b,f   Serrano Blanco, Antoni ^a,b   García Campayo, Javier ^b,g  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT OBERTA DE CATALUNYA   (Spain)

^d LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^e INSTITUT CATALÀ DE LA SALUT   (Spain)

^f UNIVERSIDAD DE MÁLAGA   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE BEHAVIORAL THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; FEMALE; FIBROMYALGIA; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SENSITIVITY ANALYSIS; SPAIN; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; PROCEDURES; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANALGESICS; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; DULOXETINE HYDROCHLORIDE; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PREGABALIN; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SURVEYS AND QUESTIONNAIRES; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84990889291     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0451-y     Document Type: Article

References (57)

1. Smith HS, Harris R, Clauw D: Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician 2011, 14:E217-E245.
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clar P: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
3. Wolfe F, Clauw DJ, Fitzcharles M-A, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB: The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010, 62:600-610.
4. Queiroz LP: Worldwide epidemiology of fibromyalgia. Curr Pain Headache Rep 2013, 17:356.
5. Leadley RM, Armstrong N, Lee YC, Allen A, Kleijnen J: Chronic diseases in the European Union: the prevalence and health cost implications of chronic pain. J Pain Palliat Care Pharmacother 2012, 26:310-325.
6. Knight T, Schaefer C, Chandran A, Zlateva G, Winkelmann A, Perrot S: Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res 2013, 5:171-180.
7. Briley M: Drugs to treat fibromyalgia: the transatlantic difference. Curr Opin Investig Drugs 2009, 11:16-18.
8. Häuser W, Bernardy K, Üçeyler N, Sommer C: Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain 2009, 145:69-81.
9. Uçeyler N, Sommer C, Walitt B, Häuser W: Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 2013, 10, CD010782.
10. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B: Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013, 1, CD010292.
11. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P: Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013, 72:955-962.
12. Williams AC, Eccleston C, Morley S: Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012, 11, CD007407.
13. Sehgal N, Colson J, Smith HS: Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy. Expert Rev Neurother 2013, 13:1201-1220.
14. Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W: Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev 2013, 9, CD009796.
15. Robinson RL, Jones ML: In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother 2006, 7:1027-1039.
16. Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G: Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Res Opin 2010, 26:965-975.
17. Lloyd A, Boomershine CS, Choy EH, Chandran A, Zlateva G: Cost effectiveness of pregabalin in the treatment of fibromyalgia: US perspective. J Med Econ 2012, 15:481-492.
18. Beard SM, Roskell N, Le TK, Zhao Y, Coleman A, Ang D, Lawson K: Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. J Med Econ 2011, 14:463-476.
19. Goossens ME, Rutten-van Mölken MP, Leidl RM, Bos SG, Vlaeyen JW, Teeken-Gruben NJ: Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. J Rheumatol 1996, 23:1246-1254.
20. Zijlstra TR, Braakman-Jansen LM, Taal E, Rasker JJ, van de Laar MA: Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford) 2007, 46:1454-1459.
21. Gusi N, Tomás-Carús P: Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial. Arthritis Res Ther 2008, 10:R24.
22. Luciano JV, Sabes-Figuera R, Cardeñosa E, T Peñarrubia-María M, Fernández-Vergel R, García-Campayo J, Knapp M, Serrano-Blanco A: Cost-utility of a psychoeducational intervention in fibromyalgia patients compared with usual care: an economic evaluation alongside a 12-month randomized controlled trial. Clin J Pain 2013, 29:702-711.
23. Alda M, Luciano JV, Andrés E, Serrano-Blanco A, Rodero B, López Del Hoyo Y, Roca M, Moreno S, Magallón R, García-Campayo J: Effectiveness of cognitive behaviour therapy for the treatment of catastrophisation in patients with fibromyalgia: a randomised controlled trial. Arthritis Res Ther 2011, 13:R173.
24. Rini C, Williams DA, Broderick JE, Keefe FJ: Meeting them where they are: using the Internet to deliver behavioral medicine interventions for pain. Transl Behav Med 2012, 2:82-92.
25. García-Campayo J, Serrano-Blanco A, Rodero B, Magallón R, Alda M, Andrés E, Luciano JV, López del Hoyo Y: Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. Trials 2009, 10:24.
26. Dworkin RH, Turk DC, Peirce-Sandner S, Baron R, Bellamy N, Burke LB, Chappell A, Chartier K, Cleeland CS, Costello A, Cowan P, Dimitrova R, Ellenberg S, Farrar JT, French JA, Gilron I, Hertz S, Jadad AR, Jay GW, Kalliomäki J, Katz NP, Kerns RD, Manning DC, McDermott MP, McGrath PJ, Narayana A, Porter L, Quessy S, Rappaport BA, Rauschkolb C, et al: Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 2010, 149:177-193.
27. Schulz KF, Altman DG, Moher D, CONSORT Group: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c332.
28. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, CHEERS Task Force: Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 2013, 11:80.
29. Yates SL, Morley S, Eccleston C, Williams A: A scale for rating the quality of psychological trials for pain. Pain 2005, 117:314-325.
30. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:34-57.
31. Ferrando L, Soto M, Bobes J, Soto O, Franco L, Gubert J: M.I.N.I. Mini International Neuropsychiatric Interview. Versión en Español 5.0.0 DSM-IV. Madrid: Instituto IAP; 1998.
32. Badia X, Schiaffino A, Alonso J, Herdman M: Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998, 7:311-322.
33. Badia X, Roset M, Montserrat S, Herdman M, Segura A: The Spanish version of EuroQol: a description and its applications: European Quality of Life scale. Med Clin (Barc) 1999, 112:79-85.
34. Vázquez-Barquero JL, Gaite L, Cuesta MJ, Garcia-Usieto E, Knapp M, Beecham J: Spanish version of the CSRI: a mental health cost evaluation interview. Arch Neurobiol (Madr) 1997, 60:171-184.
35. Patel A, Rendu A, Moran P, Leese M, Mann A, Knapp M: A comparison of two methods of collecting economic data in primary care. Family Pract 2005, 22:323-327.
36. Base de datos de costes sanitarios SOIKOS Barcelona: Now available at: Oblikue Consulting. Base de Datos de Costes Sanitarios eSALUD Barcelona. 2011. http://www.oblikue.com/bddcostes.
37. Badía X, Roset M, Herdman M, Kind P: A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001, 21:7-16.
38. van Hout BA, Al MJ, Gordon GS, Rutten FF: Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994, 3:309-319.
39. Mooney C, Duval R: Bootstrapping: A Non-parametric Approach to Statistical Inference. London: Sage; 1993.
40. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001, 10:779-787.
41. Fenwick E, Byford S: A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005, 187:106-108.
42. Royston P, White IR: Multiple imputation by chained equations (MICE): Implementation in Stata. J Stat Softw 2011, 45:1-20.
43. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York: Wiley; 1987.
44. Little RJA, Rubin DB: Statistical Analysis with Missing Data. New York: Wiley; 2002.
45. Molenberghs G, Kenward MG: Missing Data in Clinical Studies. Chichester, West Sussex: John Wiley & Sons Ltd; 2007.
46. Sicras-Mainar A, Rejas J, Navarro R, Blanca M, Morcillo A, Larios R, Velasco S, Villarroya C: Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther 2009, 11:R54.
47. Mukuria C, Brazier J, Barkham M, Connell J, Hardy G, Hutten R, Saxon D, Dent-Brown K, Parry G: Cost-effectiveness of an improving access to psychological therapies service. Br J Psychiatry 2013, 202:220-277.
48. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA: A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum 2011, 41:335-345.
49. Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, Peng X, Hann D, Wohlreich M, McCarberg B: Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the REFLECTIONS study. Pain Med 2013, 14:1400-1415.
50. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W: Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain 2013, 17:581-586.
51. Onrust S, Smit F, Willemse G, van den Bout J, Cuijpers P: Cost-utility of a visiting service for older widowed individuals: randomised trial. BMC Health Serv Res 2008, 8:128.
52. Luciano JV, Guallar JA, Aguado J, López-Del-Hoyo Y, Olivan B, Magallón R, Alda M, Serrano-Blanco A, Gili M, Garcia-Campayo J: Effectiveness of group acceptance and commitment therapy for fibromyalgia: a 6-month randomized controlled trial (EFFIGACT study). Pain 2014, 155:693-702.
53. Lauche R, Cramer H, Dobos G, Langhorst J, Schmidt S: A systematic review and meta-analysis of mindfulness-based stress reduction for the fibromyalgia syndrome. J Psychosom Res 2013, 75:500-510.
54. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, Busch A: Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther 2010, 12:R79.
55. Clauw DJ: Fibromyalgia: a clinical review. JAMA 2014, 311:1547-1555.
56. Smeets RJ, Beelen S, Goossens ME, Schouten EG, Knottnerus JA, Vlaeyen JW: Treatment expectancy and credibility are associated with the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. Clin J Pain 2008, 24:305-315.
57. Eccleston C, Palermo TM, Fisher E, Law E: Psychological interventions for parents of children and adolescents with chronic illness. Cochrane Database Syst Rev 2012, 8, CD009660.